Capital World Investors Gilead Sciences, Inc. Transaction History

Capital World Investors

$586 Billion
Q1 2024

A detailed history of Capital World Investors transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Capital World Investors holds 84,497,404 shares of GILD stock, worth $5.43 Billion. This represents 1.06% of its overall portfolio holdings.

Number of Shares

84,497,404

Previous 83,364,123 1.36%

Holding current value

$5.43 Billion

Previous $6.75 Billion 8.35%

% of portfolio

1.06%

Previous 1.23%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$71.58 - $87.29 $81.1 Million - $98.9 Million	1,133,281 Added 1.36%	84,497,404 $6.19 Billion
Q4 2023 Feb 13, 2024	BUY	$73.27 - $83.09 $120 Million - $136 Million	1,642,736 Added 2.01%	83,364,123 $6.75 Billion
Q3 2023 Nov 13, 2023	BUY	$73.94 - $80.67 $58.6 Million - $63.9 Million	792,071 Added 0.98%	81,721,387 $6.12 Billion
Q2 2023 Aug 11, 2023	BUY	$76.01 - $86.7 $337 Million - $384 Million	4,429,076 Added 5.79%	80,929,316 $6.24 Billion
Q1 2023 May 15, 2023	BUY	$77.31 - $88.08 $588 Million - $670 Million	7,607,268 Added 11.04%	76,500,240 $6.35 Billion

Q4 2022 Feb 14, 2023	BUY	$62.32 - $89.47 $694 Million - $996 Million	11,130,228 Added 19.27%	68,892,972 $5.91 Billion
Q3 2022 Nov 14, 2022	BUY	$59.54 - $68.01 $292 Million - $333 Million	4,903,276 Added 9.28%	57,762,744 $3.56 Billion
Q2 2022 Aug 15, 2022	BUY	$57.72 - $65.01 $194 Million - $218 Million	3,357,616 Added 6.78%	52,859,468 $3.27 Billion
Q1 2022 May 16, 2022	BUY	$57.92 - $72.58 $395 Million - $495 Million	6,820,228 Added 15.98%	49,501,852 $2.94 Billion
Q4 2021 Feb 14, 2022	BUY	$64.88 - $73.64 $370 Million - $420 Million	5,705,315 Added 15.43%	42,681,624 $3.1 Billion
Q3 2021 Nov 15, 2021	BUY	$67.69 - $73.03 $66.9 Million - $72.2 Million	988,974 Added 2.75%	36,976,309 $2.58 Billion
Q2 2021 Aug 16, 2021	BUY	$63.47 - $69.35 $57.4 Million - $62.7 Million	903,841 Added 2.58%	35,987,335 $2.48 Billion
Q1 2021 May 14, 2021	SELL	$60.0 - $68.46 $207 Million - $236 Million	-3,451,094 Reduced 8.96%	35,083,494 $2.27 Billion
Q4 2020 Feb 12, 2021	SELL	$56.65 - $64.55 $45.8 Million - $52.1 Million	-807,861 Reduced 2.05%	38,534,588 $2.24 Billion
Q3 2020 Nov 13, 2020	SELL	$62.1 - $78.08 $258 Million - $325 Million	-4,161,381 Reduced 9.57%	39,342,449 $2.49 Billion
Q2 2020 Aug 14, 2020	SELL	$72.34 - $84.0 $205 Million - $238 Million	-2,827,488 Reduced 6.1%	43,503,830 $3.35 Billion
Q1 2020 May 15, 2020	BUY	$62.63 - $80.22 $1.6 Billion - $2.05 Billion	25,555,467 Added 123.01%	46,331,318 $3.46 Billion
Q4 2019 Feb 18, 2020	SELL	$61.62 - $67.78 $27.9 Million - $30.7 Million	-452,643 Reduced 2.13%	20,775,851 $1.35 Billion
Q3 2019 Nov 14, 2019	SELL	$62.51 - $69.0 $31.1 Million - $34.3 Million	-497,087 Reduced 2.29%	21,228,494 $1.35 Billion
Q2 2019 Aug 14, 2019	BUY	$61.87 - $69.38 $339 Million - $381 Million	5,485,081 Added 33.77%	21,725,581 $1.47 Billion
Q1 2019 May 15, 2019	BUY	$62.53 - $70.05 $76.2 Million - $85.3 Million	1,217,836 Added 8.11%	16,240,500 $1.06 Billion
Q4 2018 Feb 14, 2019	BUY	$60.54 - $79.0 $107 Million - $140 Million	1,766,423 Added 13.33%	15,022,664 $940 Million
Q3 2018 Nov 14, 2018	BUY	$71.28 - $78.92 $93.9 Million - $104 Million	1,317,178 Added 11.03%	13,256,241 $1.02 Billion
Q2 2018 Aug 14, 2018	SELL	$64.88 - $75.68 $56.2 Million - $65.6 Million	-866,937 Reduced 6.77%	11,939,063 $846 Million
Q1 2018 May 15, 2018	BUY	$72.84 - $88.8 $59.1 Million - $72.1 Million	812,000 Added 6.77%	12,806,000 $965 Million
Q4 2017 Feb 14, 2018	BUY	$71.15 - $83.52 $495 Million - $581 Million	6,961,400 Added 138.33%	11,994,000 $859 Million
Q3 2017 Nov 14, 2017	BUY	$72.11 - $85.47 $363 Million - $430 Million	5,032,600	5,032,600 $408 Million

Others Institutions Holding GILD

# of Institutions

1,884

Shares Held

Call Options Held

8.71M

Put Options Held

8.02M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $80.6B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital World Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital World Investors with notifications on news.

Account

Capital World Investors Gilead Sciences, Inc. Transaction History